Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13310039 | 1.00 | LMNA (0.46) | LMNAALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL687784 | 0.79 | GAA (0.44) | LMNAALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL10072501 | 0.79 | GAA (0.44) | LMNAALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL688439 | 0.77 | MEN1 (0.43) | LMNAALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL10072758 | 0.77 | MEN1 (0.43) | LMNAALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL688249 | 0.76 | ALDH1A1 (0.50) | LMNAALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL10072755 | 0.76 | ALDH1A1 (0.50) | LMNAALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL13343069 | 0.75 | LMNA (0.41) | LMNAALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL688622 | 0.75 | LMNA (0.41) | LMNAALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL14358816 | 0.74 | KEAP1 (0.58) | LMNAALDH1A1KDM4EHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606248-B1 | SULFONIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE SPA (IT) | 2012-02-29 | — | — | EP | disclosed |
| US-7737139-B2 | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2010-06-15 | — | — | US | disclosed |
| US-20060258730-A1 | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | DOMPE S.P.A. (IT) | 2006-11-16 | — | — | US | disclosed |
| EP-1606248-A2 | SULFONIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompé S.P.A. (IT) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004080951-A2 | SULFONIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE S.P.A. (IT) | 2004-09-23 | — | — | WO | disclosed |
| EP-1457485-A1 | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | Dompé S.P.A. (IT) | 2004-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258730-A1 | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | CCR8, CCR1, CXCR1 | LMNA 4081/4885ALDH1A1 2078/4885KDM4E 4660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.